SI-BONE (NASDAQ:SIBN) Now Covered by Piper Sandler

Piper Sandler initiated coverage on shares of SI-BONE (NASDAQ:SIBN - Free Report) in a research report sent to investors on Thursday, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $25.00 price target on the stock.

Several other equities research analysts also recently weighed in on the stock. Needham & Company LLC reaffirmed a buy rating and set a $25.00 target price on shares of SI-BONE in a research note on Monday, December 4th. Morgan Stanley upped their target price on shares of SI-BONE from $25.00 to $26.00 and gave the stock an overweight rating in a research note on Tuesday, February 27th. Truist Financial reaffirmed a buy rating and set a $24.00 target price (down from $26.00) on shares of SI-BONE in a research note on Tuesday, February 27th. Finally, Cantor Fitzgerald reaffirmed an overweight rating and set a $25.00 target price on shares of SI-BONE in a research note on Tuesday, February 27th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of Buy and an average target price of $26.33.

SI-BONE Trading Up 3.5 %

Shares of SI-BONE stock traded up $0.55 on Thursday, reaching $16.37. The company had a trading volume of 524,496 shares, compared to its average volume of 464,370. The firm's 50 day moving average price is $18.70 and its two-hundred day moving average price is $19.05. The firm has a market cap of $672.15 million, a PE ratio of -14.62 and a beta of 1.20. SI-BONE has a 52-week low of $14.88 and a 52-week high of $29.51. The company has a debt-to-equity ratio of 0.21, a quick ratio of 8.15 and a current ratio of 9.01.

SI-BONE (NASDAQ:SIBN - Get Free Report) last released its quarterly earnings results on Monday, February 26th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.02. The business had revenue of $38.86 million for the quarter, compared to the consensus estimate of $38.60 million. SI-BONE had a negative net margin of 31.20% and a negative return on equity of 28.22%. Sell-side analysts predict that SI-BONE will post -0.97 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other SI-BONE news, insider Anthony J. Recupero sold 3,330 shares of the business's stock in a transaction that occurred on Wednesday, March 13th. The shares were sold at an average price of $16.82, for a total transaction of $56,010.60. Following the completion of the transaction, the insider now owns 255,760 shares in the company, valued at approximately $4,301,883.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Mika Nishimura sold 2,500 shares of the company's stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $16.22, for a total value of $40,550.00. Following the completion of the transaction, the director now owns 19,350 shares in the company, valued at approximately $313,857. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Anthony J. Recupero sold 3,330 shares of the stock in a transaction on Wednesday, March 13th. The stock was sold at an average price of $16.82, for a total transaction of $56,010.60. Following the sale, the insider now owns 255,760 shares of the company's stock, valued at approximately $4,301,883.20. The disclosure for this sale can be found here. Insiders sold 19,136 shares of company stock worth $375,040 in the last 90 days. Corporate insiders own 5.40% of the company's stock.

Institutional Trading of SI-BONE

Large investors have recently bought and sold shares of the business. Quarry LP acquired a new stake in SI-BONE during the 4th quarter worth $28,000. Coppell Advisory Solutions LLC acquired a new stake in SI-BONE during the 2nd quarter worth $50,000. FMR LLC boosted its stake in SI-BONE by 28.7% during the 1st quarter. FMR LLC now owns 2,160 shares of the company's stock worth $42,000 after purchasing an additional 482 shares during the period. Comerica Bank purchased a new position in SI-BONE during the 3rd quarter worth $47,000. Finally, RiverPark Advisors LLC purchased a new position in SI-BONE during the 3rd quarter worth $55,000. Institutional investors and hedge funds own 98.11% of the company's stock.

About SI-BONE

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.